{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:14:38Z","timestamp":1780758878947,"version":"3.54.1"},"reference-count":37,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s310371","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T12:40:08Z","timestamp":1646224808000},"page":"171-182","source":"Crossref","is-referenced-by-count":9,"title":["An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder"],"prefix":"10.2147","volume":"Volume 18","author":[{"given":"Jeffrey","family":"Frankel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Staskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Varano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Kennelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael A","family":"Jankowich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Haag-Molkenteller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","volume":"77","author":"Coyne","year":"2011","journal-title":"Urology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/ijcp.12164","volume":"67","author":"Coyne","year":"2013","journal-title":"Int J Clin Pract"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/nau.22295","volume":"32","author":"Coyne","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"ref5","volume-title":"Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA\/SUFU Guideline","year":"2019"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000447205","volume":"11","author":"Leron","year":"2018","journal-title":"Curr Urol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/bcp.12617","volume":"80","author":"Ruxton","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/nau.24536","volume":"40","author":"Dmochowski","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","volume":"105","author":"Benner","year":"2010","journal-title":"BJU Int"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e021889","DOI":"10.1136\/bmjopen-2018-021889","volume":"8","author":"Yeowell","year":"2018","journal-title":"BMJ Open"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ger.12304","volume":"35","author":"Tiisanoja","year":"2018","journal-title":"Gerodontology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1080\/03007995.2016.1226167","volume":"32","author":"Ganz","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/bju.13882","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.eururo.2018.10.006","volume":"75","author":"Mitcheson","year":"2019","journal-title":"Eur Urol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/JU.0000000000000807","volume":"204","author":"Staskin","year":"2020","journal-title":"J Urol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","volume":"82","author":"Herschorn","year":"2013","journal-title":"Urology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"(4):357","DOI":"10.3390\/cells8040357","volume":"8","author":"Schena","year":"2019","journal-title":"Cells"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0090-4295(01)01635-1","volume":"59","author":"Yamaguchi","year":"2002","journal-title":"Urology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/01.ju.0000067621.62736.7c","volume":"170","author":"Nomiya","year":"2003","journal-title":"J Urol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000339271","volume":"122","author":"Wachter","year":"2012","journal-title":"Cardiology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3390\/molecules23051191","volume":"23","author":"Lorca","year":"2018","journal-title":"Molecules"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1021\/acs.jmedchem.5b01372","volume":"59","author":"Edmondson","year":"2016","journal-title":"J Med Chem"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Brucker BM, McHale K, King J, Mudd PN Selectivity and maximum response of vibegron and mirabegron for \u03b23-adrenergic receptors. Proceedings of the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction 2021 Winter Meeting: Virtual Congress; February 25\u201327, 2021.","DOI":"10.1016\/j.curtheres.2022.100674"},{"key":"ref25","unstructured":"Urovant Sciences, Inc. GEMTESA\u00ae (Vibegron). [Prescribing Information]. Irvine, CA; 2020."},{"key":"ref26","first-page":"e231","volume":"201","author":"Rutman","year":"2019","journal-title":"J Urol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40261-021-01020-x","volume":"41","author":"Rutman","year":"2021","journal-title":"Clin Drug Investig"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3109\/00498254.2012.700140","volume":"42","author":"Takusagawa","year":"2012","journal-title":"Xenobiotica"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s13318-013-0133-1","volume":"39","author":"Krauwinkel","year":"2014","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1097\/JU.0000000000001574","volume":"205","author":"Staskin","year":"2021","journal-title":"J Urol"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Weber M, White WB, King J, Walker A, Mudd PN, Haag-Molkenteller C.\u00a0Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind study. Blood Pressure Monitoring. 2021;Epub ahead of print. doi:10.1097\/MBP.0000000000000572","DOI":"10.1097\/MBP.0000000000000572"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e13937","DOI":"10.1111\/ijcp.13937","volume":"75","author":"Frankel","year":"2021","journal-title":"Int J Clin Pract"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40266-020-00829-z","volume":"38","author":"Varano","year":"2021","journal-title":"Drugs Aging"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Staskin D, Frankel J, Varano S, et al. Vibegron for the treatment of patients with dry overactive bladder: a subgroup analysis from the EMPOWUR trial. J Urol. 2021;206(suppl 3):e1107-1108. doi:10.1097\/JU.0000000000002103.15","DOI":"10.1097\/JU.0000000000002103.15"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Newman D, Varano S, Shortino D, Jankowich R, Mudd PN Jr. Efficacy and safety of vibegron for the treatment of overactive bladder in women: a subgroup analysis from the EMPOWUR trial. Female Pelvic Med Reconstr Surg. 2021;27(10S):S1-S129. doi:10.1097\/SPV.0000000000001103","DOI":"10.1097\/SPV.0000000000001103"},{"key":"ref36","unstructured":"Varano S, Newman D, Shortino D, Jankowich R, Mudd PN Jr. Efficacy and safety of vibegron for the treatment of overactive bladder in women: a subgroup analysis from the EMPOWUR trial. Proceedings of the International Urogynecological Association Virtual; December 9\u201312, 2021."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.urology.2012.04.004","volume":"80","author":"Milsom","year":"2012","journal-title":"Urology"}],"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=78747","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=78747","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T06:17:13Z","timestamp":1674886633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/an-evaluation-of-the-efficacy-and-safety-of-vibegron-in-the-treatment--peer-reviewed-fulltext-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":37,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s310371","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}